MA46204A - Formes cristallines d'un inhibiteur de lysyl oxydase de type 2 et leurs procédés de fabrication - Google Patents
Formes cristallines d'un inhibiteur de lysyl oxydase de type 2 et leurs procédés de fabricationInfo
- Publication number
- MA46204A MA46204A MA046204A MA46204A MA46204A MA 46204 A MA46204 A MA 46204A MA 046204 A MA046204 A MA 046204A MA 46204 A MA46204 A MA 46204A MA 46204 A MA46204 A MA 46204A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor
- manufacturing
- methods
- crystalline forms
- lysyl oxidase
- Prior art date
Links
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 title 1
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662384596P | 2016-09-07 | 2016-09-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46204A true MA46204A (fr) | 2021-03-17 |
Family
ID=61561660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046204A MA46204A (fr) | 2016-09-07 | 2017-09-06 | Formes cristallines d'un inhibiteur de lysyl oxydase de type 2 et leurs procédés de fabrication |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10774069B2 (fr) |
| EP (1) | EP3510023B1 (fr) |
| JP (1) | JP7079772B2 (fr) |
| KR (1) | KR102587178B1 (fr) |
| CN (1) | CN109983006B (fr) |
| AU (1) | AU2017324445A1 (fr) |
| BR (1) | BR112019004517A2 (fr) |
| CA (1) | CA3036064A1 (fr) |
| EA (1) | EA201990621A1 (fr) |
| IL (1) | IL265192A (fr) |
| MA (1) | MA46204A (fr) |
| MX (1) | MX390964B (fr) |
| SG (1) | SG11201901999XA (fr) |
| WO (1) | WO2018048943A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3265445B1 (fr) * | 2015-03-06 | 2021-05-05 | Pharmakea, Inc. | Inhibiteurs de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs |
| AU2016229268B2 (en) | 2015-03-06 | 2020-09-10 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
| CA3013917A1 (fr) | 2016-02-09 | 2017-08-17 | Pharmakea, Inc. | Inhibiteurs quinolinone de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs |
| CA3036064A1 (fr) | 2016-09-07 | 2018-03-15 | Pharmakea, Inc. | Formes cristallines d'un inhibiteur de lysyl oxydase de type 2 et leurs procedes de fabrication |
| WO2018048942A1 (fr) | 2016-09-07 | 2018-03-15 | Pharmakea, Inc. | Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase |
| GB201716871D0 (en) | 2017-10-13 | 2017-11-29 | Inst Of Cancer Research: Royal Cancer Hospital | Compounds |
| CN114487139B (zh) * | 2020-10-27 | 2025-01-14 | 鲁南制药集团股份有限公司 | 一种盐酸西替利嗪有关物质的检测方法 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| IE56702B1 (en) | 1982-12-01 | 1991-11-06 | Usv Pharma Corp | Antiinflammatory antiallergic compounds |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| US7067664B1 (en) | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US6956047B1 (en) | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| HUP0204272A3 (en) | 2000-01-18 | 2005-03-29 | Pfizer Prod Inc | Corticotropin releasing factor antagonists, pharmaceutical compositions containing them and their use |
| US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| FI20030030A0 (fi) | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
| MXPA05012459A (es) | 2003-05-19 | 2006-02-22 | Irm Llc | Compuestos y composiciones inmunosupresoras. |
| WO2007016784A1 (fr) | 2005-08-11 | 2007-02-15 | Merck Frosst Canada Ltd. | Nouveau 1,2,3-tπazolylméthyle-benzothiophène substitués ou -indole et leur utilisation en tant qu’inhibiteurs de biosynthèse leukotπène |
| EP1715868A1 (fr) | 2004-01-29 | 2006-11-02 | Pfizer Products Incorporated | Combinaisons d'antipsychotiques atypiques avec derives azabicycliques d'aminomethylpyridyloxymethyl/benzioxazole pour le traitement de troubles du systeme nerveux central |
| EP1727788B1 (fr) | 2004-03-12 | 2010-07-28 | Eli Lilly And Company | Antagonistes de recepteur opioide |
| CA2557794A1 (fr) | 2004-03-15 | 2005-10-06 | Eli Lilly And Company | Antagonistes des recepteurs opioides |
| ZA200609259B (en) | 2004-04-30 | 2008-07-30 | Takeda Pharmaceutical | Heterocyclic amide compound and use thereof as an mmp-13 inhibitor |
| US7507748B2 (en) | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
| MX2007002842A (es) | 2004-09-10 | 2007-04-30 | Pfizer Prod Inc | Metodos de tratamiento de trastornos cognitivos que usan derivados azabiciclicos de piridiloximetilo y benzoisoxazol. |
| EP1791541A2 (fr) | 2004-09-10 | 2007-06-06 | Pfizer Products Inc. | Procédés de traitement des troubles del'humeur en utilisant des composés diazabicycliques contenant du benzisoxazole |
| EP1807417A2 (fr) | 2004-11-04 | 2007-07-18 | Neurogen Corporation | Dérivés hétéroaryles de pyrazolylméthyle |
| DE102004056226A1 (de) | 2004-11-22 | 2006-05-24 | Burchardt, Elmar Reinhold, Dr.Dr. | Neuartige Inhibitoren der Lysyloxidase |
| EP1846379B1 (fr) | 2005-01-31 | 2009-08-19 | Merck & Co., Inc. | Composes bicycliques antidiabetiques |
| AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| ITMI20051943A1 (it) | 2005-10-14 | 2007-04-15 | Procos Spa | Processo di risoluzione anantiomerica di 2-aminometil-pirrolidine 1-sostitute per ammidazione in presenza di lipasi |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| EP1978966A4 (fr) | 2006-01-23 | 2010-11-10 | Amira Pharmaceuticals Inc | Inhibiteurs tricycliques de la 5-lipoxygenase |
| GB0614579D0 (en) | 2006-07-21 | 2006-08-30 | Black James Foundation | Pyrimidine derivatives |
| JP2010501553A (ja) | 2006-08-18 | 2010-01-21 | アストラゼネカ アクチボラグ | Ｍｃｈｒ１アンタゴニストとしてのチエノピリミジン−４−オン誘導体およびチエノピリダジン−７−オン誘導体 |
| IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
| ES2700141T3 (es) | 2007-08-02 | 2019-02-14 | Gilead Biologics Inc | Anticuerpos inhibidores LOXL2 y usos de los mismos |
| MX2012001156A (es) | 2009-07-28 | 2012-05-08 | Anacor Pharmaceuticals Inc | Moleculas que contienen boro trisustituidas. |
| BR112012008084A2 (pt) | 2009-08-21 | 2019-09-24 | Gilead Biologics Inc | método terapêuticos e composições. |
| BR112012019693A2 (pt) | 2010-02-04 | 2017-06-20 | Gilead Biologics Inc | anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles. |
| EP2542089B1 (fr) | 2010-03-05 | 2017-01-18 | Karyopharm Therapeutics, Inc. | Modulateurs de transport nucléaire et leurs utilisations |
| PE20140146A1 (es) * | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| JP6073343B2 (ja) | 2011-10-20 | 2017-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ |
| IN2014MN01982A (fr) | 2012-04-25 | 2015-07-10 | Raqualia Pharma Inc | |
| SG11201503065PA (en) | 2012-10-30 | 2015-05-28 | Gilead Sciences Inc | Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2) |
| JP6301842B2 (ja) | 2012-12-18 | 2018-03-28 | Ｅａファーマ株式会社 | 複素環アミド誘導体及びそれを含有する医薬 |
| WO2016020732A1 (fr) | 2014-08-05 | 2016-02-11 | The University Of British Columbia | Modulateurs de caspase 6 |
| US9051320B1 (en) | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
| JP6700291B2 (ja) | 2015-02-15 | 2020-05-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | １−（ｈｅｔ）アリールスルホニル−（ピロリジン又はピペリジン）−２−カルボキサミド誘導体、及びｔｒｐａ１拮抗薬としてのそれらの使用 |
| AU2016229268B2 (en) * | 2015-03-06 | 2020-09-10 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
| EP3265445B1 (fr) | 2015-03-06 | 2021-05-05 | Pharmakea, Inc. | Inhibiteurs de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs |
| CA3036064A1 (fr) * | 2016-09-07 | 2018-03-15 | Pharmakea, Inc. | Formes cristallines d'un inhibiteur de lysyl oxydase de type 2 et leurs procedes de fabrication |
| WO2018048942A1 (fr) | 2016-09-07 | 2018-03-15 | Pharmakea, Inc. | Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase |
-
2017
- 2017-09-06 CA CA3036064A patent/CA3036064A1/fr active Pending
- 2017-09-06 WO PCT/US2017/050332 patent/WO2018048943A1/fr not_active Ceased
- 2017-09-06 JP JP2019512640A patent/JP7079772B2/ja active Active
- 2017-09-06 MX MX2019002615A patent/MX390964B/es unknown
- 2017-09-06 US US16/331,095 patent/US10774069B2/en active Active
- 2017-09-06 EP EP17849479.5A patent/EP3510023B1/fr active Active
- 2017-09-06 AU AU2017324445A patent/AU2017324445A1/en not_active Abandoned
- 2017-09-06 SG SG11201901999XA patent/SG11201901999XA/en unknown
- 2017-09-06 MA MA046204A patent/MA46204A/fr unknown
- 2017-09-06 EA EA201990621A patent/EA201990621A1/ru unknown
- 2017-09-06 CN CN201780068733.0A patent/CN109983006B/zh active Active
- 2017-09-06 KR KR1020197009870A patent/KR102587178B1/ko active Active
- 2017-09-06 BR BR112019004517-1A patent/BR112019004517A2/pt not_active IP Right Cessation
-
2019
- 2019-03-06 IL IL265192A patent/IL265192A/en unknown
-
2020
- 2020-08-03 US US16/983,759 patent/US11459309B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109983006B (zh) | 2022-02-25 |
| US10774069B2 (en) | 2020-09-15 |
| JP2019532919A (ja) | 2019-11-14 |
| CA3036064A1 (fr) | 2018-03-15 |
| WO2018048943A1 (fr) | 2018-03-15 |
| MX2019002615A (es) | 2019-10-15 |
| CN109983006A (zh) | 2019-07-05 |
| US20190202805A1 (en) | 2019-07-04 |
| JP7079772B2 (ja) | 2022-06-02 |
| AU2017324445A1 (en) | 2019-04-11 |
| BR112019004517A2 (pt) | 2019-08-13 |
| KR20190052040A (ko) | 2019-05-15 |
| US20200361901A1 (en) | 2020-11-19 |
| IL265192A (en) | 2019-05-30 |
| SG11201901999XA (en) | 2019-04-29 |
| EP3510023B1 (fr) | 2024-06-19 |
| KR102587178B1 (ko) | 2023-10-06 |
| EP3510023A1 (fr) | 2019-07-17 |
| EA201990621A1 (ru) | 2019-09-30 |
| US11459309B2 (en) | 2022-10-04 |
| EP3510023A4 (fr) | 2020-03-18 |
| MX390964B (es) | 2025-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46204A (fr) | Formes cristallines d'un inhibiteur de lysyl oxydase de type 2 et leurs procédés de fabrication | |
| MA48779A (fr) | Formes cristallines d'inhibiteur de fgfr et leurs procédés de préparation | |
| IL280659A (en) | Processes for generating engineered cells and compositions thereof | |
| EP3867936A4 (fr) | Éponges nano-graphitiques et leurs procédés de fabrication | |
| MA54875A (fr) | Compositions oligonucléotidiques et procédés associés | |
| IL285461A (en) | Processes and compounds | |
| EP3600318A4 (fr) | Procédés d'utilisation d'inhibiteurs d'ehmt2 | |
| EP3380101A4 (fr) | Composés inhibiteurs d'eif4-a et procédés associés | |
| EP4358732A4 (fr) | Procédés | |
| EP3455895A4 (fr) | Compositions et procédés pour la fabrication d'électrode | |
| EP3947366C0 (fr) | Inhibiteurs d'hpk1 | |
| MA46203A (fr) | Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase | |
| IL287668A (en) | Crystalline forms of a btk inhibitor | |
| EP3962457A4 (fr) | Composition cannabinoïde et procédés de fabrication | |
| MA48793A (fr) | Procédés de fabrication et d'utilisation d'inhibiteurs de pde9 | |
| DK3833665T3 (da) | Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser | |
| EP4006031A4 (fr) | Inhibiteur de jak2 sélectif de dihydro-pyrrolo-pyrimidine | |
| EP3469078A4 (fr) | Procédés et compositions d'amplification d'acide nucléique | |
| EP3307081A4 (fr) | Compositions de lécithine et procédés de fabrication et d'utilisation de ces compositions de lécithine | |
| EP3436039A4 (fr) | Formes polymorphes d'un oxystérol et procédés de fabrication de ces dernières | |
| EP3765619C0 (fr) | Inhibiteurs de micro-arn 22 | |
| EP4053514A4 (fr) | Biocapteur de plante | |
| JP1728698S (ja) | インゴット | |
| EP3504546A4 (fr) | Compositions de marqueurs et leurs procédés de fabrication et d'utilisation | |
| EP4402133A4 (fr) | Inhibiteurs de protoporphyrinogène oxydase |